Sarepta sees early success with RNAi drugs from Arrowhead
Source: BioPharma Dive - Latest News
Long-awaited results from Phase 1/2 studies lifted Sarepta’s stock and, according to the company, suggest potential for two medicines to treat muscle-weakening conditions.